drugset
drugset / Trial / NCT06774625

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

NCT06774625 ↗

Phase 2 Completed 250 enrolled Latigo Biotherapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn if LTG-001 works to treat pain after third molar removal surgery in adults. It will also learn about the safety of LTG-001. The main questions it aims to answer are: Does drug LTG-001 treat the acute pain after surgical removal of impacted third molars (wisdom teeth) over 12 hours? How tolerable is LTG-001 after surgical removal of impacted third molars (wisdom teeth) over 12 hours? Researchers in Part 1 will compare drug LTG-001 to a placebo (a look-alike substance that contains no drug) and in Part 2 to a placebo and a comparator to see if drug LTG-001 treats the post-surgical pain. Participants will: Take LTG-001 one time after the surgical removal of impacted third molars. Remain at the clinic for 12 hours after study dosing and return after a week for a safety check up. Report the pain relief during the 12 hours after dosing to record changes in the post-operative pain

Timeline

Start
2024-12-19
Primary completion
2025-08-08
Completion
2025-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject LTG-001 Unknown — —
Comparator Suzetrigine Small molecule — —

Indications

No indication recorded.